Autoimmune Diseases
Welcome,         Profile    Billing    Logout  
 294 Companies   490 Products   490 Products   198 Mechanisms of Action   25 Trials   7787 News 


«12...1011121314151617181920...156157»
  • ||||||||||  elcubragistat (Lu AG06466) / Lundbeck
    Trial initiation date:  Central Pain Study for ABX-1431 (clinicaltrials.gov) -  Aug 3, 2017   
    P1,  N=32, Recruiting, 
    Active, not recruiting --> Completed | N=200 --> 241 Initiation date: May 2017 --> Aug 2017
  • ||||||||||  cyclophosphamide / Generic mfg.
    Trial initiation date, Trial termination, Trial primary completion date:  Immuno-ablation With Chemoimmunoradiation and Autologous Stem Cell Transplant for Churg-Strauss Syndrome (clinicaltrials.gov) -  Aug 1, 2017   
    P,  N=1, Terminated, 
    Active, not recruiting --> Completed | Trial primary completion date: Mar 2017 --> May 2017 Initiation date: Aug 2016 --> Apr 2016 | Not yet recruiting --> Terminated | Trial primary completion date: Aug 2021 --> Jul 2016; PI left the institution
  • ||||||||||  Trial completion, Enrollment change:  Use of Thermal and 3D Imaging to Quantify Arthritis (clinicaltrials.gov) -  Jul 31, 2017   
    P=N/A,  N=157, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | N=230 --> 157
  • ||||||||||  Phase classification:  Cementless Alumina-Alumina Total Hip and Hybrid (clinicaltrials.gov) -  Jul 28, 2017   
    P=N/A,  N=342, Completed, 
    Active, not recruiting --> Completed Phase classification: P3 --> P=N/A
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  Evaluation of Coagulation in Multiple Sclerosis (clinicaltrials.gov) -  Jul 28, 2017   
    P=N/A,  N=69, Completed, 
    Phase classification: P3 --> P=N/A Recruiting --> Completed | N=100 --> 69 | Trial primary completion date: Dec 2016 --> May 2016
  • ||||||||||  petesicatib (RG7625) / Roche
    Trial completion, Enrollment change, Trial primary completion date:  A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome (clinicaltrials.gov) -  Jul 28, 2017   
    P2a,  N=75, Completed, 
    Recruiting --> Completed | N=100 --> 69 | Trial primary completion date: Dec 2016 --> May 2016 Active, not recruiting --> Completed | N=62 --> 75 | Trial primary completion date: Dec 2017 --> Jun 2017
  • ||||||||||  Trial completion, Trial primary completion date, HEOR:  QUALVIE-SEP: Disability, Perceived Social Support and Quality of Life in Multiple Sclerosis (clinicaltrials.gov) -  Jul 28, 2017   
    P=N/A,  N=150, Completed, 
    Active, not recruiting --> Completed | N=62 --> 75 | Trial primary completion date: Dec 2017 --> Jun 2017 Recruiting --> Completed | Trial primary completion date: Aug 2016 --> Mar 2017
  • ||||||||||  Enrollment closed, Enrollment change, Trial primary completion date:  NISSC: EBMT ADWP Prospective Non Interventional Study : AutoHSCT in SSc Patients (clinicaltrials.gov) -  Jul 26, 2017   
    P=N/A,  N=82, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=50 --> 82 | Trial primary completion date: Dec 2015 --> Dec 2017
  • ||||||||||  Trial primary completion date:  MESEMS: MEsenchymal StEm Cells for Multiple Sclerosis (clinicaltrials.gov) -  Jul 25, 2017   
    P1/2,  N=12, Recruiting, 
    Recruiting --> Active, not recruiting | N=50 --> 82 | Trial primary completion date: Dec 2015 --> Dec 2017 Trial primary completion date: May 2017 --> May 2018
  • ||||||||||  Humalog pen (insulin lispro) / Eli Lilly
    Trial primary completion date:  Environmental Effects Type 1 Diabetes Mellitus (clinicaltrials.gov) -  Jul 24, 2017   
    P=N/A,  N=10, Recruiting, 
    Trial primary completion date: Jul 2017 --> Dec 2017 Trial primary completion date: Jun 2017 --> Dec 2017
  • ||||||||||  Enrollment status, Trial primary completion date:  Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis (clinicaltrials.gov) -  Jul 19, 2017   
    P=N/A,  N=1920, Enrolling by invitation, 
    Terminated --> Completed Recruiting --> Enrolling by invitation | Trial primary completion date: Apr 2017 --> Apr 2018
  • ||||||||||  losartan potassium / Generic mfg.
    Enrollment closed, Trial primary completion date:  Efficacy and Safety of Losartan in Children With Ig A Nephropathy (clinicaltrials.gov) -  Jul 17, 2017   
    P3,  N=37, Active, not recruiting, 
    Initiation date: May 2017 --> Aug 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Dec 2016
  • ||||||||||  Trial primary completion date:  Accu-Chek (clinicaltrials.gov) -  Jul 13, 2017   
    P=N/A,  N=200, Completed, 
    Completed --> Terminated; Screening discontinued early due to slow patient enrollment Trial primary completion date: Aug 2016 --> Jan 2017
  • ||||||||||  Trial completion:  Telemedicine Program in Type 1 Diabetes and CSII (clinicaltrials.gov) -  Jul 13, 2017   
    P=N/A,  N=51, Completed, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2016 --> Mar 2018 Active, not recruiting --> Completed